Senesco Technologies, Inc. closed on its previously announced private placement to institutional and accredited investors, consisting of 1,595,651 shares of common stock and warrants to purchase 797,836 shares of common stock. Aggregate gross proceeds to the Company were approximately $3.37 million. In connection with the private placement, Senesco has agreed to file a registration statement on Form S-3 to register the shares of common stock and the shares underlying the warrants.

Oppenheimer & Co. acted as the placement agent for this transaction.

Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates cell life. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has undertaken preclinical research in certain areas of human health.

Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco partners with leading-edge companies and earns research and development fees for applying its technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey, and utilizes research laboratories at universities and research centers throughout North America.